Delivery of Dissociated Islets Cells within Microporous Annealed Particle Scaffold to Treat Type 1 Diabetes.
Delivery of Dissociated Islets Cells within Microporous Annealed Particle Scaffold to Treat Type 1 Diabetes.
复制标题
在微孔退火颗粒支架内递送解离的胰岛细胞来治疗 1 型糖尿病。
DOI：
10.1002/adtp.202200064
复制
发表时间：
2022
影响因子：
4.6
通讯作者：
Griffin,Donald
中科院分区：
文献类型：
--
作者：
Roosa,ColleenA;Ma,Mingyang;Chhabra,Preeti;Brayman,Kenneth;Griffin,Donald
1型糖尿病（T1 D）是由胰腺中产生胰岛素的β细胞的自身免疫性丧失引起的。唯一不需要外源性胰岛素的血糖控制临床方法是胰腺或胰岛移植。不幸的是，供体胰岛是稀缺的，移植后立即有大量的胰岛损失，部分原因是局部炎症反应。干细胞衍生的β细胞的递送（例如，来自诱导多能干细胞）和解离的胰岛细胞有望作为T1 D的治疗方法;然而，这些细胞通常需要在植入前在体外重新聚集。微孔支架已显示出作为胰岛素产生细胞的组织、存活和功能的载体的高潜力。在这项研究中，使用微孔退火颗粒（MAP）支架的酶促解离的胰岛细胞，一个模型β细胞源，支架的互连孔内的交付进行了研究。发现基于MAP的细胞递送使得解离的胰岛细胞能够在体外和体内T1 D小鼠模型中存活和发挥功能。
Type 1 diabetes (T1D) is caused by the autoimmune loss of insulin‐producing beta cells in the pancreas. The only clinical approach to patient management of blood glucose that doesn't require exogenous insulin is pancreas or islet transplantation. Unfortunately, donor islets are scarce and there is substantial islet loss immediately after transplantation due, in part, to the local inflammatory response. The delivery of stem cell‐derived beta cells (e.g., from induced pluripotent stem cells) and dissociated islet cells hold promise as a treatment for T1D; however, these cells typically require re‐aggregation in vitro prior to implantation. Microporous scaffolds have shown high potential to serve as a vehicle for organization, survival, and function of insulin‐producing cells. In this study, the use of microporous annealed particle (MAP) scaffold for delivery of enzymatically dissociated islet cells, a model beta cell source, within the scaffold's interconnected pores is investigated. It is found that MAP‐based cell delivery enables survival and function of dissociated islets cells both in vitro and in an in vivo mouse model of T1D.